Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • The share is getting closer to its long-term support in weekly data, at USD 62.11, which offers good timing for buyers.
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The tendency within the weekly time frame is positive above the technical support level at 62.11 USD
Weaknesses
  • Low profitability weakens the company.
  • One of the major weak points of the company is its financial situation.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's earnings releases usually do not meet expectations.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
ULTRAGENYX PHARMACEUTICAL I..33.23%3 249
GILEAD SCIENCES1.59%95 398
VERTEX PHARMACEUTICALS20.99%46 338
REGENERON PHARMACEUTICALS2.18%40 777
NEUROCRINE BIOSCIENCES, INC..41.84%10 086
SAREPTA THERAPEUTICS INC136.05%8 671
GENMAB-11.78%8 632
BLUEBIRD BIO INC-29.94%6 829
BIOCON LTD16.63%5 124
LOXO ONCOLOGY INC88.48%4 999
EXELIXIS, INC.-47.70%4 840
HUALAN BIOLOGICAL ENGINEERI..--.--%4 827
PEPTIDREAM INC10.18%4 523
TONGHUA DONGBAO PHARMACEUTI..-33.64%4 503
NOVOCURE LTD118.37%4 196
AGIOS PHARMACEUTICALS INC14.76%3 821
More Results
Financials ($)
Sales 2018 56,1 M
EBIT 2018 -390 M
Net income 2018 -227 M
Finance 2018 255 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 53,3x
EV / Sales 2019 28,1x
Capitalization 3 249 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period : Day
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Duration : Period : Week
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener